The Head-To-Head Comparison: ContraFect Corporation (CFRX) versus Grifols, (GRFS)

The Head-To-Head Comparison: ContraFect Corporation (CFRX) versus Grifols, (GRFS)

ContraFect Corporation (NASDAQ: CFRX) and Grifols, (NASDAQ:GRFS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.


Grifols, pays an annual dividend of $0.28 per share and has a dividend yield of 1.3%. ContraFect Corporation does not pay a dividend. Grifols, pays out 31.1% of its earnings in the form of a dividend.

Analyst Ratings

This is a breakdown of recent ratings for ContraFect Corporation and Grifols,, as provided by MarketBeat.

ContraFect Corporation presently has a consensus price target of $5.00, suggesting a potential upside of 395.05%. Given ContraFect Corporation’s stronger consensus rating and higher probable upside, equities analysts plainly believe ContraFect Corporation is more favorable than Grifols,.


This table compares ContraFect Corporation and Grifols,’s net margins, return on equity and return on assets.

Earnings & Valuation

This table compares ContraFect Corporation and Grifols,’s top-line revenue, earnings per share and valuation.

Grifols, has higher revenue and earnings than ContraFect Corporation. ContraFect Corporation is trading at a lower price-to-earnings ratio than Grifols,, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

ContraFect Corporation has a beta of -0.82, meaning that its stock price is 182% less volatile than the S&P 500. Comparatively, Grifols, has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Insider and Institutional Ownership

24.5% of ContraFect Corporation shares are held by institutional investors. Comparatively, 21.9% of Grifols, shares are held by institutional investors. 9.3% of ContraFect Corporation shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.


Grifols, beats ContraFect Corporation on 9 of the 14 factors compared between the two stocks.

About ContraFect Corporation

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

About Grifols,

Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Related posts

Leave a Comment